Last reviewed · How we verify

NCT06894147: GRFT-PRF

Genicular Radiofrequency Ablation Versus Pulsed Radiofrequency

Active, enrolled NA Last updated 25 March 2025
What this trial tests

NA trial testing Genicular nerve pulse radiofrequency in Osteoarthritis of Knee in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 April 2024
Primary endpoint
30 April 2025
30 May 2025

Quick facts

Lead sponsorAnkara City Hospital Bilkent
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingtriple
Primary purposetreatment
Enrollment80
Start date1 April 2024
Primary completion30 April 2025
Estimated completion30 May 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ankara City Hospital Bilkent

Who can join

18 and older, any sex, with Osteoarthritis of Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the effectiveness of two treatments-genicular nerve radiofrequency ablation and pulsed radiofrequency-in reducing pain and improving function in osteoarthritis patients. These techniques, used after diagnostic nerve blocks, aim to provide long-lasting pain relief. Despite both being found effective, no clear consensus exists on which method is superior. The study seeks to compare these techniques and contribute new insights to the existing literature.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoarthritis of Knee

Currently open trials in the same condition.

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06894147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing